Circulating histones as potential biomarkers of MASLD-MASH-HCC progression.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: MASLD (n = 25), MASH (n = 25), HCC (n = 40), and 30 healthy controls
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Our data indicate plasma histones H2A and H4 as new biomarkers of liver disease progression. The identification of histone-based biomarkers using imaging flow cytometry could provide a rapid approach to discriminate between non-MASH and MASH, and to predict the risk of HCC development.
[BACKGROUND] Reliable biomarkers are warranted to identify patients with metabolic dysfunction-associated steatotic liver disease (MASLD), including metabolic dysfunction-associated steatohepatitis (M
- 표본수 (n) 25
APA
Tsoneva DK, Buzova D, et al. (2025). Circulating histones as potential biomarkers of MASLD-MASH-HCC progression.. Epigenomics, 17(18), 1435-1446. https://doi.org/10.1080/17501911.2025.2611415
MLA
Tsoneva DK, et al.. "Circulating histones as potential biomarkers of MASLD-MASH-HCC progression.." Epigenomics, vol. 17, no. 18, 2025, pp. 1435-1446.
PMID
41486803
Abstract
[BACKGROUND] Reliable biomarkers are warranted to identify patients with metabolic dysfunction-associated steatotic liver disease (MASLD), including metabolic dysfunction-associated steatohepatitis (MASH), at risk for developing hepatocellular carcinoma (HCC).
[RESEARCH AND METHODS] We evaluated whether circulating histones can predict this risk. Plasma histones were measured using imaging flow cytometry in patients with MASLD (n = 25), MASH (n = 25), HCC (n = 40), and 30 healthy controls.
[RESULTS] We detected ( < 0.05), compared to controls: 1) elevated levels of H2A, H3, H2A/H2B/H3/H4, macroH2A1.1, macroH2A1.2 in MASLD/MASH and HCC; 2) decreased levels of macroH2A1.2/H2B/H3/H4 in MASLD/MASH and increased in HCC; 3) reduced H4 levels discriminating between MASH and non-MASH. Machine-learning analysis showed that being diabetic/dyslipidemic, having decreased H2A ( = 0.002) and H4 ( = 0.0156) levels favor MASH.
[CONCLUSIONS] Our data indicate plasma histones H2A and H4 as new biomarkers of liver disease progression. The identification of histone-based biomarkers using imaging flow cytometry could provide a rapid approach to discriminate between non-MASH and MASH, and to predict the risk of HCC development.
[RESEARCH AND METHODS] We evaluated whether circulating histones can predict this risk. Plasma histones were measured using imaging flow cytometry in patients with MASLD (n = 25), MASH (n = 25), HCC (n = 40), and 30 healthy controls.
[RESULTS] We detected ( < 0.05), compared to controls: 1) elevated levels of H2A, H3, H2A/H2B/H3/H4, macroH2A1.1, macroH2A1.2 in MASLD/MASH and HCC; 2) decreased levels of macroH2A1.2/H2B/H3/H4 in MASLD/MASH and increased in HCC; 3) reduced H4 levels discriminating between MASH and non-MASH. Machine-learning analysis showed that being diabetic/dyslipidemic, having decreased H2A ( = 0.002) and H4 ( = 0.0156) levels favor MASH.
[CONCLUSIONS] Our data indicate plasma histones H2A and H4 as new biomarkers of liver disease progression. The identification of histone-based biomarkers using imaging flow cytometry could provide a rapid approach to discriminate between non-MASH and MASH, and to predict the risk of HCC development.
MeSH Terms
Humans; Histones; Male; Middle Aged; Female; Disease Progression; Carcinoma, Hepatocellular; Liver Neoplasms; Biomarkers; Fatty Liver; Aged; Case-Control Studies; Biomarkers, Tumor; Adult